Amgen "overweight," target price reduced

07.03.07 - HSBC

NEW YORK, March 7 (newratings.com) - In a research note published yesterday, analysts at HSBC reiterate their "overweight" rating on Amgen Inc (AMGN). The target price has been reduced from $90 to $89.